CN109527577A - 一种具有解酒护肝功能的组合物 - Google Patents
一种具有解酒护肝功能的组合物 Download PDFInfo
- Publication number
- CN109527577A CN109527577A CN201910057182.9A CN201910057182A CN109527577A CN 109527577 A CN109527577 A CN 109527577A CN 201910057182 A CN201910057182 A CN 201910057182A CN 109527577 A CN109527577 A CN 109527577A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- sobering
- cordyceps sinensis
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000006870 function Effects 0.000 title claims abstract description 64
- 241000255789 Bombyx mori Species 0.000 claims abstract description 126
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 67
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 44
- 244000197580 Poria cocos Species 0.000 claims abstract description 44
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 44
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 43
- 235000008434 ginseng Nutrition 0.000 claims abstract description 43
- 240000008042 Zea mays Species 0.000 claims abstract description 40
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 39
- 235000005822 corn Nutrition 0.000 claims abstract description 39
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 30
- 210000000582 semen Anatomy 0.000 claims abstract description 28
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 24
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 24
- 240000001949 Taraxacum officinale Species 0.000 claims abstract 2
- 241000245665 Taraxacum Species 0.000 claims description 28
- 241001264174 Cordyceps militaris Species 0.000 claims description 26
- 238000012258 culturing Methods 0.000 claims description 22
- 230000033228 biological regulation Effects 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 239000011888 foil Substances 0.000 claims description 14
- 239000004033 plastic Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 11
- 241000169546 Lycium ruthenicum Species 0.000 claims description 11
- 238000009395 breeding Methods 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 241000382353 Pupa Species 0.000 claims description 9
- 244000025254 Cannabis sativa Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000009738 saturating Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 125000006850 spacer group Chemical group 0.000 claims description 7
- 208000007848 Alcoholism Diseases 0.000 claims description 6
- 201000007930 alcohol dependence Diseases 0.000 claims description 5
- 238000003672 processing method Methods 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 244000202052 Poncirus trifoliata Species 0.000 claims description 2
- 235000000404 Poncirus trifoliata Nutrition 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 52
- 239000003814 drug Substances 0.000 abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 18
- 239000000126 substance Substances 0.000 abstract description 16
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 10
- 210000002784 stomach Anatomy 0.000 abstract description 9
- 230000035622 drinking Effects 0.000 abstract description 8
- 231100000753 hepatic injury Toxicity 0.000 abstract description 8
- 235000008216 herbs Nutrition 0.000 abstract description 7
- 206010067125 Liver injury Diseases 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 210000000232 gallbladder Anatomy 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 6
- 230000010354 integration Effects 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 150000003254 radicals Chemical class 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 231100000234 hepatic damage Toxicity 0.000 abstract description 4
- 230000008818 liver damage Effects 0.000 abstract description 4
- 210000002966 serum Anatomy 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 30
- 239000001963 growth medium Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 25
- 235000019441 ethanol Nutrition 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 10
- 230000036039 immunity Effects 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 235000004936 Bromus mango Nutrition 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 8
- 241001093152 Mangifera Species 0.000 description 8
- 235000014826 Mangifera indica Nutrition 0.000 description 8
- 235000009184 Spondias indica Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 235000013312 flour Nutrition 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 7
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 6
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 241000219780 Pueraria Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000001147 anti-toxic effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000001465 calcium Nutrition 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000012907 honey Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 230000001624 sedative effect Effects 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001151 other effect Effects 0.000 description 3
- -1 panaxan Natural products 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010010075 Coma hepatic Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 241001522129 Pinellia Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 230000005961 cardioprotection Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229940108928 copper Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 201000001059 hepatic coma Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 2
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000003375 plant hormone Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000007686 potassium Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 238000010129 solution processing Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000317410 Arisaema dracontium Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 235000002239 Dracunculus vulgaris Nutrition 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 240000006859 Jasminum officinale Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010046685 Rho Factor Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002416 angiotensin derivative Substances 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229930186938 hovenoside Natural products 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- SVICABYXKQIXBM-UHFFFAOYSA-L potassium malate Chemical compound [K+].[K+].[O-]C(=O)C(O)CC([O-])=O SVICABYXKQIXBM-UHFFFAOYSA-L 0.000 description 1
- 239000001415 potassium malate Substances 0.000 description 1
- 235000011033 potassium malate Nutrition 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Insects & Arthropods (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种药食同源的一种具有解酒护肝功能的组合物。该组合物是由活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽组成。本发明提供的中药成分选用药食同源的动植物提取而成,并配以玉米肽,组方配比科学,不添加任何化学物及西药等人工合成组分,安全无毒副作用,具有清热解毒、降血糖、软化血管、祛风通络、对抗自由基过氧化等作用,能抑制胃对酒精的吸收,还能护肝治胆,醒酒、强化蛋白,对实验性肝损伤有保护作用,并可降低血清谷丙转氨酶,促进肝损伤的修复。此外,本发明提供的组合物不但功效显著,而且使用方便,具有很好的市场前景。
Description
技术领域
本发明涉及食药领域,具体涉及一种药食同源的一种具有解酒护肝功能的组合物。
背景技术
肝是人体的一个重要器官,负责管理身体三大货币(气、血、水)流通。情绪、睡眠、饮食甚至药物等,均会影响肝的疏泄功能。
保肝,顾名思义就是保护肝脏的意思。肝脏不但是人体中最大的消化器官,还是人体中一个重要的解毒器官,要减轻肝脏负担得从这二大方面来减负。中医认为,肝主面,肝气疏泄条达则气色红润,神清气爽。肝脏是人体不可或缺的一个"化工厂"。肝脏是身体重要的排毒器官,肠胃道所吸收的有毒物质,都要在肝脏经过解毒程序变为无毒物质,再经过胆汁或尿液排出体外。如果肝脏长期超负荷工作,太多的身体毒素无法及时排解出去,反映到人的皮肤上就是脸色暗哑、色素沉淀。可见,肝脏在人的代谢、消化、解毒、凝血、免疫调节等方面均起着非常重要的作用。
在生活中,对肝伤害最大莫过于长期酗酒抽烟,这些都是伤害肝脏的行为,对身体产生很大的危害,特别是对消化道、肝脏的损伤尤为严重,酒精加快加深肝损伤;长期如此,会大大增加患上肝硬化和脂肪肝的可能性。而我国酒文化历史悠久且盛行,大有“无酒不成席”、“无酒不欢”之风。我国喜酒者人数众多,约有60~75%的成年的男性经常饮酒,且过量饮酒诱发的疾病比例逐年增长。过量饮酒易不仅导致肝损伤及相应的肝病变,而且会引发其他疾病,尤甚者会引起人体生理功能紊乱乃至死亡。过量饮酒导致的酒精性肝损伤已经成为肝病患得的最主要因素之一,于此同时过度酗酒导致患高血压疾病、胃癌等恶性疾、蛋白质等物质发生代谢紊乱时有发生。引起肝脏损伤最常见的毒物是酒精,过量饮酒导致的肝脏损伤已经成为世界性的医学难题。酒精性肝病(Alcoholic Liver Disease,ALD)是因为长期的大量饮酒而导致的脂肪性肝脏疾病,如果不及时控制可恶化为酒精性肝炎、肝纤维化、肝硬化甚至原发性肝癌。
因此,如何醒酒、解酒及减少饮酒对人体胃肠、肝脏等脏器的伤害的需求已迫在眉睫,开发有效的解酒药物具有重要的意义和广阔的市场前景。
发明内容
本发明的目的在于提供一种药食同源的一种具有解酒护肝功能的组合物。该组合物是由活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽组成。本发明提供的中药成分选用药食同源的动植物提取而成,并配以玉米肽,组方配比科学,不添加任何化学物及西药等人工合成组分,安全无毒副作用,具有清热解毒、降血糖、软化血管、祛风通络、对抗自由基过氧化等作用,能抑制胃对酒精的吸收,还能护肝治胆,醒酒、强化蛋白,对实验性肝损伤有保护作用,并可降低血清谷丙转氨酶 ,促进肝损伤的修复。此外,本发明提供的组合物不但功效显著,而且使用方便,具有很好的市场前景。
为实现上述目的,本发明提供以下技术方案为:
1.一种具有解酒护肝功能的组合物,技术方案中在于:该组合物是由6~15份活体蚕蛹培育虫草,18~30份葛根,8~16份黑枸杞,8~16份人参,8~12份蒲公英,5~12份枳椇子,2~8份蚕蛹、1~5份茯苓,15~26份玉米肽组成。
优选地,一种具有解酒护肝功能的组合物还包括:活体蚕蛹培育虫草13份,葛根22份,玉米肽20份、黑枸杞11份,人参12份,蒲公英9份,枳椇子8份,蚕蛹3份,茯苓2份。
2.一种具有解酒护肝功能的组合物,技术方案中在于所述的活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
3.一种具有解酒护肝功能的组合物,技术方案中在于所述的活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
4.一种具有解酒护肝功能的组合物,技术方案中在于所述的葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓的提取物含量比例都是10:1以上。
5.一种具有解酒护肝功能的组合物,技术方案中在于所述的玉米肽的肽含量都是90%以上。
6.一种具有解酒护肝功能的组合物,技术方案中在于所述的组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
7.一种具有解酒护肝功能的组合物,技术方案中所述的组合物在制备具有解酒护肝的产品或产品添加剂中的应用。
所述的活体蚕蛹培育虫草蛹虫草富含虫草素、虫草酸、多糖等物质。中医认为,蛹虫草既能补肺阴,又能补肾阳,主治肾虚,阳痿遗精,腰膝酸痛,病后虚弱,久咳虚弱,劳咳痰血,自汗盗汗等,是一种能同时平衡、调节阴阳的中药。 蛹虫草中含有大量的虫草素,虫草素的特殊医疗保健功能已经引起国内外专家的高度重视,已有不少以虫草素为主的保健品、保健食品、化妆品、药品等投放市场。在中国也已将由虫草素合成的治疗白血病的新药进入期临床试用。蛹虫草的保健功能成分不仅有虫草素,还有虫草多糖是国际医学公认的人体免疫增强剂。中医认为其起扶正固本作用,对老年性慢性支气管炎、肺原性心脏病有显著疗效,能提高肝脏解毒能力,起护肝作用,提高身体抗病毒和抗辐射能力。虫草酸即D-甘露醇是治疗心脑血管疾病的基本药物,具有清除自由基、扩张血管、降低血压的作用。核苷酸具有抑制血小板聚集、防止心脑血栓形成,消除黄褐斑、老年斑、青春痘,抗衰防皱,养颜美容等。
所述的玉米肽是从玉米中提取的蛋白质,经过定向酶切及特定小肽分离技术获得的小分子多肽物质。玉米肽具有如下特点及功效:
1.营养丰富:含有人体必须的各种氨基酸,提供氨基酸及肽能营养。
2.降低血压:玉米低聚肽可抑制血管紧张素转换酶的活性,作为一种血管紧张素的竞争性抑制剂,减轻血管紧张读,产生降压作用。高血压患者口服 44 小时后可使血压下降。也可预防高血压的发生,对正常人起保健作用。玉米肽的氨基酸组成中,支链氨基酸(亮氨酸、异亮氨酸、缬氨酸)含量很高。有报道,肝昏迷、肝性脑病患者血中支链氨基酸含量下降,输入高含量支链氨基酸可使病情得到缓解,高支链输液广泛应用于肝昏迷、肝硬化、重症肝炎和慢性肝炎的治疗。
3.醒酒作用:具有抑制酒精中毒,玉米肽能抑制胃对酒精的吸收,增加体内乙醇脱氢酶和乙醛脱氢酶的活性,促进酒精在体内的代谢和排出。
4、其它作用:本产品除了含降血压小肽外,其它的小肽具有抗疲劳、保肝、提高机体免疫力等功能。
5、易吸收:优于氨基酸或蛋白质的吸收。
6、溶解性:在大范围PH下完全溶于水,无浑浊现象和沉淀物产生。
7、稳定性:对热稳定,组份不改变,功能不丧失。
8、安全性:天然食品蛋白,安全可靠,无毒副作用。具有如下功效:
所述的枳椇子,别名拐枣。拐枣有很高的营养价值。据科研部门分析测定,其肉质果梗中含蔗糖24%、葡萄糖9.5%、果糖7.92%。风味颇佳,可作为生食果品。因而有"糖果树"的盛名,又有"鸡爪梨"、"甜半夜"之雅称。此外,还含有丰富的有机酸、苹果酸钾等无机盐类。含有多种维生素和18种人体必需的氨基酸,还含铁、磷、钙、铜、锰、锌等营养微量元素和一些生物碱。每百克拐枣肉质梗含粗脂肪74毫克、粗蛋白3.07毫克、总酸345.8毫克、维生素C16.29毫克。是一种很具有开发价值的野生果类资源。此外,枳椇子具有如下功效:
1.止渴除烦:枳椇子中含有大量的葡萄糖、蔗糖、果糖、有机酸、无机盐、维生素等,能生津止渴,清热除烦,并能给人体补充养分,增强机体的抗病能力。《本草拾遗》 :“止渴除烦,去膈上热,润五脏,利大小便,功用如蜜。”
2.醒酒安神:枳椇子中含有大量的葡萄糖、有机酸,既能扩充人体的血容量,又能解酒毒,故有醒酒安神的作用。《本草》只言木能败酒,而丹溪朱氏治酒病往往用其实,其功当亦同也。
3.通利二便:枳椇子含有大量水分、葡萄糖、有机盐、脂类物质,具有促进尿液排泄,加速肠道蠕动等作用,故能通利二便。
4.祛风通络:枳椇子中含有大量的钙和枳椇子皂甙,具有中枢抑制作用,能够抗惊厥,防止手足抽搐痉挛,可用来治疗风湿痹痛麻木之症。《滇南本草》:"治一切左瘫右痪,风湿麻木,能解酒毒;或泡酒服之,亦能舒筋络。
5.降血压:研究发现,枳椇子中含有麦草碱、B-咔啉、枳椇甙C、D、G、H、鼠李碱等,具有抗脂质过氧化和降低血压等作用。
所述的人参自古誉为"百草之王"、"滋阴补生,扶正固本"之极品,含多种皂甙和多糖类成分。人参具有如下功效:
1.调节中枢神经系统:人参能调节中枢神经系统,改善大脑的兴奋与抑制过程,使之趋于平衡;能提高脑力与体力劳动的能力,提高工作效率,并有抗疲劳的作用。
2.有促进大脑的功能:可以帮助人们提高学习记忆能力,因为人参里面含有对我们记忆力的物质。
3.改善心脏功能:人参能增加心肌收缩力,减慢心率,增加心输出量与冠脉血流量,可抗心肌缺血与心律失常。对心脏功能、心血管、血流都有一定的影响。人参有明显的耐缺氧作用,其制剂可有效地对抗窦性心率失常。人参皂苷可加快脂质代谢,并具有明显降低高胆固醇的作用。小剂量人参可使麻醉动物血压轻度上升,大剂量则使血压下降。不同的人参制剂对离体蟾蜍心脏及在体兔、猫、犬心脏皆有增强其功能的作用,并可改善其心室纤颤时的心肌无力
4.降血糖作用:人参中含有人参皂苷和人参多糖。尤其是人参皂苷Rb2有明显的降血糖作用,此外人参多糖(或糖肽类)是人参中另一类降血糖成分。
5.增强机体的免疫功能:人参立含有可以调节我们人体的免疫功能的活性成分,对免疫低下的人还有帮助提高的作用。
6.提高对有害刺激的抵御能力:可增强机体的应激能力和适应性,人参中含有人参苷,可以提高抗应激作用。可以抗缺氧、耐高温和低温的能力。
7.抗肿瘤作用:人参中的人参皂苷、人参多糖、人参烯醇类、人参炔三醇和挥发油类物质。这些物质对肿瘤有一定的抑制作用,但是机理是十分复杂的。
8.抗氧化作用:人参中含有多种抗氧化物质,人参皂苷、人参聚乙炔类化合物和人参二醇皂苷等。这些化合物有抗脂质过氧化作用,是抗衰老作用的基础。除了抗衰老作用外,对神经、内分泌、免疫功能及物质代谢等生理功能有调节作用。此外,人参还具有抗病毒、抗休克、减肥等多方面的作用。人参虽然是价值较高的补品,但并非人人适用。人参中的蛋白质因子能抑制脂肪分解,加重血管壁脂质沉积,故有冠心病、高血压、脑血管硬化、糖尿病、脉管炎害应慎服人参。血液黏稠度升高,会使血液流通不畅,中医称之为血瘀。人参有促进红细胞生长的作用,红细胞增多,血液站稠度会更高。
所述的茯苓,又称玉灵、茯灵、万灵桂、茯菟。中医认为茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。宁心安神,败毒抗癌。药性平和,利湿而不伤正气。所含茯苓酸具有增强免疫力、抗肿瘤以及镇静、降血糖等的作用。可松弛消化道平滑肌,抑制胃酸分泌,防止肝细胞坏死,抗菌等功效。此外, 茯苓具有如下功效:
1.宁心安神:茯苓所含成分对中枢神经系统有一定作用,有养心安神的功效,常食用茯苓可以有效改善气血不足导致的心悸失眠,还能消除水肿,缓解压力。
2.利尿:茯苓的主要功效就是利水渗湿,而且药效比较平和,一般人都你能够接受并且服用,不会伤害到身体中的正气,没有副作用,能够快速的缓解小便不利等症状,不管是湿热还是寒湿症状,都可以使用茯苓,除了治病还能养生,快速的促进身体的健康。
3.抗菌消炎:茯苓含有的茯苓多糖、茯苓酸等物质,有一定的抗菌消炎作用,药理作用表明,茯苓对于大肠杆菌、金黄色葡萄球菌等都有着一定的抑制效果。常食用茯苓泡水喝,可以起到较好的抗菌消炎作用。
4.降血糖:茯苓进入身体之后能够有效的降低血糖含量,适合高血糖患者服用。这些患者平时应该多将茯苓泡水喝,能够降低身体中的血糖含量,促进身体健康。
5.保护心脏:茯苓有一定的镇静作用,有宁心安神的功效,常食用茯苓可以缓解心悸的症状,还能起到保护心脏的作用。用茯苓配伍黄芪、人参等补气健脾中药,药效更佳。
6.增强免疫力:茯苓聚糖对正常及荷瘤小鼠的免疫功能有增强作用,能增强小鼠巨噬细胞吞噬功能。茯苓可以有提高免疫力的作用,对于抗菌抗病毒起到了很好的作用和效果。
7.祛痰止咳:痰湿入络,肩背酸痛茯苓既能利水渗湿,又具健脾作用,对于脾虚不能运化水湿,停聚化生痰饮之症,具有治疗作用。可用半夏、陈皮同用,也可配桂枝、白术同用。治痰湿入络、肩酸背痛,可配半夏、枳壳同用。
8.保护肠胃:科学家在家兔身上进行了实验,发现服用茯苓能够有效的预防肠胃溃疡,还能够治疗肠管松弛的情况,并且对于胃酸也有一定的下降作用。
9.抗癌:服用茯苓对于肝癌、食道癌、肺癌以及鼻咽癌等多种癌症都有很不错的治疗效果。为什么茯苓具有抗肿瘤的作用呢,这是因为茯苓中含有多糖体,这种物质具有非常强烈的抗肿瘤功效,能够抑制肿瘤在身体中的生长。
10.健脾祛湿:茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
所述的葛根为豆科植物野葛的干燥根,习称野葛。据《本草纲目》和《中华人民共和国药典》记载,葛根是植物黄金,含有人体必需的氨基酸13种,尤其是人体不能合成的必需的氨基酸含量更高。所含的有效活性成份有异黄酮、葛根紊、葛根甙、生物碱等物质,铁、钙、锰等人体必需的微量元也丰富。葛根及其制品有升阳解饥,生津止渴,清火、排毒、降血脂、降血压、降血糖、降胆固醇,预防心脑血管等功效。还能提高肝细胞的再生能力,恢复正常肝脏机能,促进胆汁分泌,防止脂肪在肝脏堆积。促进新陈代谢,加强肝脏解毒功能,防止酒精对肝脏的损伤。此外,据现代医学研究,葛根异黄酮具有防癌抗癌和植物激素作用。饮用价值极高,在日本被称为“长寿龙根”。植物激素是山药宝中之宝,国际让素有“亚洲人参”之美誉。
所述的蒲公英(拉丁学名:Taraxacum mongolicum Hand.-Mazz.)菊科,蒲公英属多年生草本植物。生蒲公英富含维生素A、维生素C及钾,也含有铁、钙、维生素B2、维生素B1、镁、维生素B6、叶酸及铜。具体的元素含量主要是水分,每60克生蒲公英叶含水分86%,蛋白质1.6克,碳水化合物5.3克,热量约有108.8千焦。蒲公英具有如下功效:
1.清热解毒:蒲公英的医药功效,首先就是适合用在各式各样的热毒疾病方面,对于人体出现的很多热症抑或是化脓性疾病的治疗都很好。尤其遇到由肝热所引起的严重发红、肿痛的情况,其清肝热的功效非常显著。
2.美颜养容:蒲公英的叶子中有大量蛋白质、脂肪、微量元素、碳水化合物、维生素等,日常服用蒲公英水可以帮助改善皮肤炎、湿疹等肌肤疾病。
3.防治肿瘤:现代研究还发现,蒲公英的叶子具有防肿瘤的作用。经常服用能起到提高身体免疫力。
4.护肝治胆:蒲公英是天然的利尿剂和助消化圣品;含有丰富的矿物质,不仅能帮助预防缺铁引起的贫血症,而且它的大量钾成分还可以和钠一起共同调节体内的水盐平衡,并使心率正常;含有丰富的蛋黄素,可以预防肝硬化,增强肝和胆的功能。
所述的黑枸杞具有如下功效:
1. 提高免疫力:枸杞的性味甘平,中医认为,它能够滋补肝肾、益精明目和养血、增强人们的免疫力。所以说,对于现代人来说,枸杞最实用的功效就是抗疲劳和降低血压。
2.抗肿瘤作用:中国医学科学院研究证实,枸杞不但能提高人体免疫力,在抗肿瘤治疗中能减轻环磷酰胺的毒副作用,促进造血功能恢复,升高周围血的白细胞数,对机体产生保护作用。
3.延缓衰老:枸杞子含有丰富的枸杞多糖、β-胡萝卜素、维生素E、硒及黄酮类等抗氧化物质,有较好的抗氧化作用。枸杞子可对抗自由基过氧化,减轻自由基过氧化损伤,从而有助于延缓衰老,延长寿命。
4.保肝护肝:枸杞子能抑制脂肪在肝细胞内沉积,并促进肝细胞新生。枸杞多糖对实验性肝损伤有保护作用,可降低血清谷丙转氨酶 ,促进肝损伤的修复。
5.降糖护肾:枸杞还能够降血糖、软化血管、降低血液中的胆固醇、甘油三酯水平,对脂肪肝和糖尿病患者具有一定的疗效。据临床医学验证,枸杞还能治疗慢性肾衰竭。
6.养颜美容:常吃枸杞可以美容,这点很多人都不知道。这是因为,枸杞可以提高皮肤吸收氧分的能力,另外,还能起到美白作用。
所述的蚕蛹肽具有如下功效:
1.提高免疫力:蚕蛹能产生具有药理学活性的物质,可有效提高人体内白细胞水平,从而提高人体免疫功能,延缓人体机能衰老,蚕蛹油可以降血脂、降胆固醇、对治疗高胆固醇血症和改善肝功能有显著作用。
2.营养丰富:蚕蛹含有丰富的蛋白质和多种氨基酸,是体弱、病后、老人及妇女产后的高级营养补品。用于脾虚气弱或营养不良,消瘦乏力;脾虚,消渴口干,虚烦发热。
3.抗三高:适宜高血压病、高脂血症、脂肪肝、糖尿病之人食用;适宜肺结核、身体瘦弱之人食用;适宜小儿疳瘦者食用;适宜慢性胃炎、胃下垂之人食用。
4.补肾壮阳:蛹味甘、辛、咸,性温。入脾、胃经;可补肾壮阳,补虚劳,祛风湿。
本发明提供的上述技术方案具有以下优点:
1.本发明中,采集了鲜活的蚕蛹为载体,培育的蛹虫草子实体中虫草多糖、虫草素、虫草酸、腺苷等物质含量好,功效优越。
2.本发明提供的解酒护肝的组合物中的中药成分选用药食同源的动植物提取而成,并配以玉米肽,组方配比科学,不添加任何化学物及西药等人工合成组分,安全无毒副作用,具有清热解毒、降血糖、软化血管、祛风通络、对抗自由基过氧化等作用,能抑制胃对酒精的吸收,还能护肝治胆,醒酒、强化蛋白,对实验性肝损伤有保护作用,并可降低血清谷丙转氨酶 ,促进肝损伤的修复。
4.本发明中,中药成分的提取物含量比例都是10:1以上,而且能够在最大限度的保留各原料活性成分的同时,充分释放各原料组分中的有效成分;添加的玉米肽的肽含量都是90%以上了,可有效的帮助人体吸收各种养分,最终使其具有优异的功效。
5.本发明中,提供的解酒护肝组合物制备方法工艺稳定、产率高、质量好、能耗低、原材料广泛、工序简单节省、可操作性强,有利于后续的规模化应用。此外,本发明提供的组合物不但功效显著,而且使用方便,具有很好的市场前景。
具体实施方式
下面将对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚的说明本发明的技术方案,因此只作为实例,而不能以此来限制本发明的保护范围。
下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为自常规试剂商店购买得到的。
1.一种具有解酒护肝功能的组合物,技术方案中在于:该组合物是由6~15份活体蚕蛹培育虫草,18~30份葛根,8~16份黑枸杞,8~16份人参,8~12份蒲公英,5~12份枳椇子,2~8份蚕蛹、1~5份茯苓,15~26份玉米肽组成。
优选地,一种具有解酒护肝功能的组合物还包括:活体蚕蛹培育虫草13份,葛根22份,玉米肽20份、黑枸杞11份,人参12份,蒲公英9份,枳椇子8份,蚕蛹3份,茯苓2份。
2.一种具有解酒护肝功能的组合物,技术方案中在于所述的活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
3.一种具有解酒护肝功能的组合物,技术方案中在于所述的活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
4.一种具有解酒护肝功能的组合物,技术方案中在于所述的葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓的提取物含量比例都是10:1以上。
5.一种具有解酒护肝功能的组合物,技术方案中在于所述的玉米肽的肽含量都是90%以上。
6.一种具有解酒护肝功能的组合物,技术方案中在于所述的组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
7.一种具有解酒护肝功能的组合物,技术方案中所述的组合物在制备具有解酒护肝的产品或产品添加剂中的应用。
下面结合具体实施方式进行说明:
实施例一
1.一种具有解酒护肝功能的组合物,由下述原料组分组成:活体蚕蛹培育虫草13份,葛根22份,玉米肽20份、黑枸杞11份,人参12份,蒲公英9份,枳椇子8份,蚕蛹3份,茯苓2份。
2.活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
3.活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
4.蚕蛹虫草菌丝体的培育方法如下:
(1)培养基是由50份蚕蛹粉,30份黄豆粉、10份玉米粉和10份芒果果粉组成;
(2)选择纯度高、感染力强、无杂菌的蛹虫草菌种为种源;
(3)将上述蚕蛹粉、黄豆粉、玉米粉和芒果果粉混合起来并搅拌均匀得培养基,然后拌入适量的清水使培养基的含水量达到50~55%,最后将培养基分装至菌丝体培养容器中;
(4)按照常规方法把培养基进行消毒,然后在无菌环境下接入蛹虫草菌种;
(5)把接好种的培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝吃透培养基,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养,一直培养至菌丝转色,最后将转色的菌丝连同培养基一并放置于放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目的成品蚕蛹虫草菌丝体。
5.组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
实施例二
1.一种具有解酒护肝功能的组合物,由下述原料组分组成:活体蚕蛹培育虫草8份,葛根28份,玉米肽22份、黑枸杞13份,人参12份,蒲公英9份,枳椇子8份,蚕蛹3份,茯苓2份。
2.活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
3.活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
4.蚕蛹虫草菌丝体的培育方法如下:
(1)培养基是由50份蚕蛹粉,30份黄豆粉、10份玉米粉和10份芒果果粉组成;
(2)选择纯度高、感染力强、无杂菌的蛹虫草菌种为种源;
(3)将上述蚕蛹粉、黄豆粉、玉米粉和芒果果粉混合起来并搅拌均匀得培养基,然后拌入适量的清水使培养基的含水量达到50~55%,最后将培养基分装至菌丝体培养容器中;
(4)按照常规方法把培养基进行消毒,然后在无菌环境下接入蛹虫草菌种;
(5)把接好种的培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝吃透培养基,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养,一直培养至菌丝转色,最后将转色的菌丝连同培养基一并放置于放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目的成品蚕蛹虫草菌丝体。
5.组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
实施例三
1.一种具有解酒护肝功能的组合物,由下述原料组分组成:活体蚕蛹培育虫草9份,葛根26份,玉米肽22份、黑枸杞12份,人参12份,蒲公英10份,枳椇子12份,蚕蛹3份,茯苓2份。
2.活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
3.活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
4.蚕蛹虫草菌丝体的培育方法如下:
(1)培养基是由55份蚕蛹粉,25份黄豆粉、10份玉米粉和10份芒果果粉组成;
(2)选择纯度高、感染力强、无杂菌的蛹虫草菌种为种源;
(3)将上述蚕蛹粉、黄豆粉、玉米粉和芒果果粉混合起来并搅拌均匀得培养基,然后拌入适量的清水使培养基的含水量达到50~55%,最后将培养基分装至菌丝体培养容器中;
(4)按照常规方法把培养基进行消毒,然后在无菌环境下接入蛹虫草菌种;
(5)把接好种的培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝吃透培养基,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养,一直培养至菌丝转色,最后将转色的菌丝连同培养基一并放置于放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目的成品蚕蛹虫草菌丝体。
5.组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
实施例四
1.一种具有解酒护肝功能的组合物,由下述原料组分组成:活体蚕蛹培育虫草10份,葛根20份,玉米肽30份、黑枸杞13份,人参10份,蒲公英8份,枳椇子12份,蚕蛹3份,茯苓2份。
2.活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
3.活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
4.蚕蛹虫草菌丝体的培育方法如下:
(1)培养基是由60份蚕蛹粉,20份黄豆粉、10份玉米粉和10份芒果果粉组成;
(2)选择纯度高、感染力强、无杂菌的蛹虫草菌种为种源;
(3)将上述蚕蛹粉、黄豆粉、玉米粉和芒果果粉混合起来并搅拌均匀得培养基,然后拌入适量的清水使培养基的含水量达到50~55%,最后将培养基分装至菌丝体培养容器中;
(4)按照常规方法把培养基进行消毒,然后在无菌环境下接入蛹虫草菌种;
(5)把接好种的培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝吃透培养基,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养,一直培养至菌丝转色,最后将转色的菌丝连同培养基一并放置于放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目的成品蚕蛹虫草菌丝体。
5.组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
Claims (8)
1.一种具有解酒护肝功能的组合物,其特征在于:该组合物是由6~15份活体蚕蛹培育虫草,18~30份葛根,8~16份黑枸杞,8~16份人参,8~12份蒲公英,5~12份枳椇子,2~8份蚕蛹、1~5份茯苓,15~26份玉米肽组成。
2.根据权利要求1所述的一种具有解酒护肝功能的组合物,其特征在于具体由如下原料组分制成:
活体蚕蛹培育虫草13份,葛根22份,玉米肽20份、黑枸杞11份,人参12份,蒲公英9份,枳椇子8份,蚕蛹3份,茯苓2份。
3.根据权利要求1~2任一项所述一种具有解酒护肝功能的组合物,其特征在于所述的活体蚕蛹培育虫草的培育方法如下:
(1)采集鲜活的蚕蛹为载体;
(2)选择纯度高、感染力强、无杂菌的蛹虫草液体菌种为种源;
(3)将蚕蛹、菌种和注射器一并放置于接种箱中,然后做常规消毒;
(4)用注射器经吸满蛹虫草液体菌种,并由注射器在活体蚕蛹的体节间隔膜处注入蛹虫草液体菌种;
(5)用卫生纸将接过种的活体蚕蛹其表面所沾附的水分抹干净,再把活体蚕蛹摆放在底部垫铺有2~3层卫生纸的培养容器中,然后把培养容器移至前期培养室中,并将环境温度调控在17°C以下,同时将培养环境调控为弱光培养;
(6)15天左右,菌丝长透蛹体,蛹体死亡,蛹体也变得稍坚实,即可将蛹体移至培养容器中,容器口用塑料膜封住,并用针将塑料膜扎透若干个透气微孔,然后将培养容器移至后期培养室中,并将环境温度调控在22°C~28°C,环境湿度调控在70~80%,同时将培养环境调控为强光培养;
(7)培养50~60天后,蛹体长出的草达到3~6公分时得活体蚕蛹培育虫草成品。
4.根据权利要求1~3任一项所述一种具有解酒护肝功能的组合物,其特征在于所述的活体蚕蛹培育虫草的加工方法如下:
将活体蚕蛹培育虫草成品放置于烘房中,在60°C以下环境烘干至物料含水量低于5%,然后粉碎至能过80~100目。
5.根据权利要求1~2任一项所述一种具有解酒护肝功能的组合物,其特征在于所述的葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓的提取物含量比例都是10:1以上。
6.根据权利要求1~2任一项所述一种具有解酒护肝功能的组合物,其特征在于所述的玉米肽的肽含量都是90%以上。
7.根据权利要求1~6任一项所述一种具有解酒护肝功能的组合物,其特征在于所述的组合物制备方法如下:
将上述活体蚕蛹虫草、葛根、人参、枸杞、蒲公英、枳椇子、蚕蛹、茯苓和玉米肽按照原料组分按质量份计进行组合起来得一种具有解酒护肝功能的组合物。
8.根据权利要求1~8任一项所述一种具有解酒护肝功能的组合物,所述的组合物在制备具有解酒护肝的产品或产品添加剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910057182.9A CN109527577A (zh) | 2019-01-22 | 2019-01-22 | 一种具有解酒护肝功能的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910057182.9A CN109527577A (zh) | 2019-01-22 | 2019-01-22 | 一种具有解酒护肝功能的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109527577A true CN109527577A (zh) | 2019-03-29 |
Family
ID=65838032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910057182.9A Pending CN109527577A (zh) | 2019-01-22 | 2019-01-22 | 一种具有解酒护肝功能的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109527577A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109965169A (zh) * | 2019-05-05 | 2019-07-05 | 河南成如祥商贸有限公司 | 一种具有醒酒护肝功能的饮料及其制备方法 |
CN113122419A (zh) * | 2021-03-23 | 2021-07-16 | 贵州利生香中药科技有限公司 | 一种天然中药材的白酒小曲配方及制备工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105395702A (zh) * | 2015-12-09 | 2016-03-16 | 江苏神华药业有限公司 | 一种具有解酒保肝抗疲劳的组合物及其应用 |
CN108477367A (zh) * | 2017-08-01 | 2018-09-04 | 楼良水 | 醒酒护肝的虫草低聚肽压片糖果 |
-
2019
- 2019-01-22 CN CN201910057182.9A patent/CN109527577A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105395702A (zh) * | 2015-12-09 | 2016-03-16 | 江苏神华药业有限公司 | 一种具有解酒保肝抗疲劳的组合物及其应用 |
CN108477367A (zh) * | 2017-08-01 | 2018-09-04 | 楼良水 | 醒酒护肝的虫草低聚肽压片糖果 |
Non-Patent Citations (4)
Title |
---|
姜锡瑞等主编: "《生物发酵产业技术》", 30 May 2016, 中国轻工业出版社 * |
尹常健著: "《肝病用药十讲》", 30 June 2018, 中国中医药出版社 * |
王伟等: "寒地蛹虫草人工栽培技术", 《现代农业科技》 * |
黄世敬等主编: "《中药临床合理应用手册》", 30 April 2009, 金盾出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109965169A (zh) * | 2019-05-05 | 2019-07-05 | 河南成如祥商贸有限公司 | 一种具有醒酒护肝功能的饮料及其制备方法 |
CN113122419A (zh) * | 2021-03-23 | 2021-07-16 | 贵州利生香中药科技有限公司 | 一种天然中药材的白酒小曲配方及制备工艺 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101695376B (zh) | 预防糖尿病的保健食品 | |
KR101090284B1 (ko) | 홍삼과 녹용 추출물을 포함하는 드링크제 및 그의 제조방법 | |
CN107156623A (zh) | 一种复合谷物混合物及其制备方法 | |
CN109550040A (zh) | 一种增强免疫力的中药多肽组合物 | |
CN107114663A (zh) | 一种果蔬养胃米粉及其制备方法 | |
CN103859378A (zh) | 一种有助于降低血糖的养生保健食品配方及其制备方法 | |
CN107156828A (zh) | 一种适用于炎性肠病患者的全营养配方食品 | |
CN106244371A (zh) | 一种降血糖黄精葡萄保健酒及其生产工艺 | |
CN1676036A (zh) | 灵芝金刚根保健食品及其制备方法 | |
CN107223846A (zh) | 一种适合中老年人的杂粮保健粉 | |
JP2016077283A (ja) | 農産物と穀物菌糸体とが混合され、発酵された抗癌、抗糖尿、免疫増進用の発酵禅食組成物及びその製造方法{Fermentedfoodcompositioncomprisingagriculturalproductsandmyceliummixtureforpreventingortratingcancer、diabeticsandimprovingimmunefunction、andpreparationmethodthereof} | |
CN108497474A (zh) | 一种全植物药食糊 | |
CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
CN101401651A (zh) | 烹调用的中药组合物 | |
CN103141849A (zh) | 一种可延缓衰老的膳食养生粉制备工艺 | |
CN107019208A (zh) | 一种中药酵素及其制备方法 | |
CN110093239A (zh) | 一种诺丽配制酒及其制备方法 | |
CN104544084A (zh) | 一种用于糖尿病患者的保健食品 | |
CN109043325A (zh) | 一种食用复合菌粉 | |
CN107125751A (zh) | 龟粉、制备方法及其应用 | |
CN103689561A (zh) | 一种有助于降脂减肥的养生保健食品配方及其制备方法 | |
CN105361149A (zh) | 一种青稞虫草糁子营养粉及其制备方法 | |
CN114748583A (zh) | 一种滋补养生的中药药酒 | |
CN1528182A (zh) | 一种保健食品及其制备方法 | |
CN110679935A (zh) | 一种牛蒡人参精华膏及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190329 |
|
WD01 | Invention patent application deemed withdrawn after publication |